PROGRAM
and
ABSTRACTS

Fourth
International
Conference
on Malignant Lymphoma

June, 6-9, 1990

Lugano, Switzerland
PROGRAM
and
ABSTRACTS

Fourth
International
Conference
on Malignant Lymphoma
June, 6-9, 1990

Lugano, Switzerland

Organizing Committee:
F. Cavalli (Bellinzona),
G. Bonadonna (Milan),
T.A. Lister (London),
M. Rozencweig (Wallingford),
J.E. Ultmann (Chicago),
R. Zittoun (Paris)

Advisory Board:
C.W. Berard (Memphis),
S.B. Murphy (Chicago),
H. Rappaport (Duarte),
S.A. Rosenberg (Stanford),
R.C. Young (Philadelphia)

Sponsored by Swiss Group for Clinical Cancer Research (SAKK) and Lega Ticinese Contro il Cancro
THE TANDEM MAKES ITS WAY
TUESDAY, JUNE 5, 1990

WORKSHOP ON PROGNOSTIC FACTORS IN AGGRESSIVE NHL'S
(ATTENDANCE BY INVITATION ONLY)

WEDNESDAY, JUNE 6, 1990

8:30 - 11:30 A.M. SATELLITE SYMPOSIUM (Room A)
CLINICAL EVALUATION OF NOVANTRONE IN LYMPHOMA THERAPY

11:30 - 3:30 P.M. SATELLITE SYMPOSIUM (Room B)
NEW ASPECTS OF INTERFERON THERAPY IN HAEMATOLOGICAL MALIGNANCIES AND LYMPHOMAS

12:00 - 3:30 P.M. SATELLITE SYMPOSIUM (Room A)
RECENT ADVANCES IN LYMPHOMA TREATMENT

3:30 - 4:30 P.M. MEET THE PROFESSORS (Rooms BI, BII, C, E, F, G) REPEATED TWICE!
5:00 - 6:00 P.M.

4:30 - 6:00 P.M. POSTER SESSION I (Villa Ciani)

6:30 - 6:45 P.M. OPENING CEREMONY (Room A)

6:45 - 7:45 P.M. HENRY KAPLAN MEMORIAL LECTURE (Room A)
THE INFLUENCE OF INFORMATION ON DRUG RESISTANCE ON PROTOCOL DESIGN

THURSDAY, JUNE 7, 1990

8:30 - 11:45 A.M. SESSION 1 - BIOLOGY OF LYMPHOMAS I (Room A)

1:00 - 1:45 P.M. KEY NOTE LECTURE (Room A)
MOLECULAR GENETICS OF HUMAN B CELL NEOPLASIA.

1:50 - 2:50 P.M. SESSION 2 - GENERAL SESSION ON HD (Room A)

3:00 - 5:30 P.M. SESSION 3 - PROFFERED PAPERS ON HD (Room A)

5:30 - 6:30 P.M. POSTER SESSION II (Villa Ciani)

3:00 - 5:30 P.M. SESSION 4 - WORKSHOP ON "NEW DIAGNOSTIC TOOLS IN LYMPHOMA"
(Room B)

3:00 - 5:35 P.M. SESSION 5 - LYMPHOMA IN CHILDHOOD (Room C)
FRIDAY, JUNE 8, 1990

8:00 - 9:00 A.M. POSTER SESSION III (VILLA CIANI)
9:00 - 11:45 A.M. Session 6 - BIOLOGY OF LYMPHOMAS II (Room A)
1:00 - 1:45 P.M. KEY NOTE LECTURE (Room A)
THE ROLE OF GROWTH FACTORS IN HAEMOPOIESIS: BIOLOGICAL AND CLINICAL IMPLICATIONS.
1:50 - 2:50 P.M. Session 7 - GENERAL SESSION ON NHL (Room A)
2:55 - 6:00 P.M. Session 8 - PROFFERED PAPERS ON NHL (Room A)
3:00 - 5:15 P.M. Session 9 - WORKSHOP ON GROWTH FACTORS (Room B I)
3:00 - 6:00 P.M. Session 10 - CLINICAL-PATHOLOGICAL CORRELATION (Room B II)
6:30 P.M. BUFFET DINNER (MAIN HALL PALAZZO DEI CONGRESSI)
8:00 P.M. PERFORMANCE “DIMITRI”, THEATRE (Room A)

SATURDAY, JUNE 9, 1990

9:00 - 11:30 A.M. Session 11 - FUTURE PROSPECTS (Room A)
12:00 ADJOURN

1:30 - 3:30 P.M. SECOND EUROPEAN EXAMINATION ON MEDICAL ONCOLOGY (Room C)
WEDNESDAY, JUNE 6, 1990
3:30 - 7:45 P.M.
------------------------

3:30 - 4:30 P.M.
MEET THE PROFESSOR (REPEATED TWICE)

5:00 - 6:00 P.M.
Bone Marrow Transplantation (Room B I)
J.O. Armitage, Omaha, USA

Peripheral T-cell Lymphomas (Room E)
R. Zittoun, Paris, France

CNS-Lymphoma (Room F)
B.P. O'Neill, Rochester, USA

Follicular Lymphomas (Room C)
T.A. Lister, London, United Kingdom

Special Situations in HD and NHL (Room B II)
J.E. Ulmann, Chicago, USA

Modern Radiology in the Staging of Lymphomas (Room G)
R. Musumeci, Milan, Italy

4:30 - 6:00 P.M.
Poster Session I (Villa Ciani)
Biological Studies

6:30 P.M.
Opening Ceremony (Room A)
Welcome and Introductory Remarks
F. Cavalli, Bellinzona, Switzerland

6:45 P.M.
Henry Kaplan Memorial Lecture (Room A)
The Influence of Information on Drug Resistance on Protocol Design
V.T. DeVita, New York, USA
<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
<th>TITLE, AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 A.M.</td>
<td>NATURE OF STERNBERG-REED CELLS AND OTHER BIOLOGICAL PROBLEMS.</td>
<td>H. STEIN, BERLIN, WEST-GERMANY</td>
</tr>
<tr>
<td>8:55</td>
<td>LOW SERUM INTERLEUKIN-2 RECEPTOR LEVELS CORRELATE WITH A GOOD PROGNOSIS IN</td>
<td>M. PFREUNDSCHUH, COLOGNE, WEST-GERMANY</td>
</tr>
<tr>
<td></td>
<td>PATIENTS WITH HODGKIN'S DISEASE.</td>
<td></td>
</tr>
<tr>
<td>9:10</td>
<td>AN EPIDEMIOLOGIC VIEW OF THE NEW CYTOGENETIC FINDINGS IN HODGKIN'S DISEASE.</td>
<td>N.E. MUELLER, BOSTON, USA</td>
</tr>
<tr>
<td>9:35</td>
<td>NON HODGKIN'S LYMPHOMA ARISING IN PATIENTS TREATED FOR HODGKIN'S DISEASE</td>
<td>M.H. BENNETT, ET AL, LONDON, UNITED KINGDOM</td>
</tr>
<tr>
<td></td>
<td>IN THE BNLI - A 20 YEAR EXPERIENCE.</td>
<td></td>
</tr>
<tr>
<td>9:50</td>
<td>INTERMISSION</td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td>HODGKIN'S DISEASE AND ITS RELATION TO NON HODGKIN'S LYMPHOMA.</td>
<td>M.L. HANSMANN, KIEL, WEST-GERMANY</td>
</tr>
<tr>
<td>10:35</td>
<td>PERIPHERAL T-CELL LYMPHOMAS.</td>
<td>H. STEIN, BERLIN, WEST-GERMANY</td>
</tr>
<tr>
<td>11:00</td>
<td>CURRENT EPIDEMIOLOGIC AND THERAPEUTIC SITUATION IN AIDS.</td>
<td>S. BRODER, BETHESDA, USA</td>
</tr>
<tr>
<td>11:30</td>
<td>QUANTITATIVE MAGNETIC RESONANCE STUDIES OF LUMBAR VERTEBRAL MARROW IN</td>
<td>S.R. SMITH, ET AL, LIVERPOOL, UNITED KINGDOM</td>
</tr>
<tr>
<td></td>
<td>PATIENTS WITH REFRACTORY OR RELapsed HODGKIN'S DISEASE.</td>
<td></td>
</tr>
<tr>
<td>12:00 NOON</td>
<td>LUNCH (ROOM B)</td>
<td></td>
</tr>
<tr>
<td>1:00-1:45 P.M.</td>
<td>KEY NOTE LECTURE (ROOM A)</td>
<td>MOLECULAR GENETICS OF HUMAN B CELL NEOPLASIA.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C.M. CROCE, PHILADELPHIA, USA</td>
</tr>
</tbody>
</table>
**Thursday, June 7, 1990**  
**1:50 - 2:50 P.M.**

---

**Session 2 - General Session on HD (Room A)**  
**Chairman: T.J. McElwain**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:50</td>
<td>10</td>
<td>The Continuing Challenge of Hodgkin's Disease</td>
<td>S.A. Rosenberg, Stanford, USA</td>
</tr>
<tr>
<td>2:10</td>
<td>11</td>
<td>Alternating Versus Hybrid MOPP-ABVD in Hodgkin's Disease</td>
<td>G. Bonadonna, Milan, Italy</td>
</tr>
<tr>
<td>2:30</td>
<td>12</td>
<td>Long Term Toxicity of Hodgkin's Disease Treatment</td>
<td>J.M. Cosset, Villejuif, France</td>
</tr>
</tbody>
</table>

---

**Session 3 - Proffered Papers on HD (Room A)**  
**Chairmen: S.A. Rosenberg and D. Crowther**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00</td>
<td>13</td>
<td>A Randomised Study of Adjuvant MVPP Chemotherapy After Mantle Radiotherapy in PS IA-IIB Hodgkin's Disease: 10 Year Follow Up.</td>
<td>H. Anderson, et al, Manchester, United Kingdom</td>
</tr>
<tr>
<td>3:30</td>
<td>15</td>
<td>Combination Chemotherapy with Chlorambucil, Vinblastine, Prednisolone and Procarbazine in Hodgkin's Disease: 14 Year Follow Up on 284 Patients.</td>
<td>T.J. McElwain, et al, Sutton, United Kingdom</td>
</tr>
<tr>
<td>3:45</td>
<td>16</td>
<td>MOPP vs ABVD vs MOPP Alternating with ABVD as Treatment for Advanced Hodgkin's Disease: Results at a Median Follow-Up of 4 Years.</td>
<td>J.R. Anderson, et al, Omaha, USA</td>
</tr>
<tr>
<td>4:15</td>
<td>18</td>
<td>Salvage Radiotherapy in Recurrent Hodgkin's Disease.</td>
<td>M. Brada, et al, Sutton, United Kingdom</td>
</tr>
</tbody>
</table>
THURSDAY, JUNE 7, 1990
3:00 - 5:30 P.M. (CONTINUED)

4:30  19  AUTLOGOUS BONE MARROW TRANSPLANTATION FOR REFRACTORY OR RELAPSED HODGKIN'S DISEASE. THE MEMORIAL SLOAN-KETTINGER CANCER CENTER EXPERIENCE USING HIGH DOSE CHEMOTHERAPY WITH AND WITHOUT HYPERFRACTIONATED ACCELERATED TOTAL LYMPHOID IRRADIATION.
J. YAHALOM, ET AL, NEW YORK, USA

4:45  20  100 CASES OF RELAPSED HODGKIN'S DISEASE TREATED WITH BEAM CHEMOTHERAPY AND ABMT IN A SINGLE CENTRE.
A. McMillan, ET AL, LONDON, UNITED KINGDOM

5:00  21  TREATMENT OUTCOME IN HODGKIN'S DISEASE IN PATIENTS ABOVE THE AGE OF 60: A POPULATION-BASED STUDY.
G. Enblad, ET AL, UPPSALA, SWEDEN

5:15  22  HIV-RELATED HODGKIN'S DISEASE IN 50 INTRAVENOUS USERS.
S. Monfardini, ET AL, AVIANO, ITALY

5:30 - 6:30 P.M.  POSTER SESSION II (VILLA CIANI)
HODGKIN'S DISEASE

SESSION 4 - WORKSHOP ON "NEW DIAGNOSTIC TOOLS IN LYMPHOMA" (ROOM B)
CHAIRMEN: C.W. BERARD AND J. COSTA

3:00 - 5:30 P.M.

3:00 P.M.  23  SOME ANIMAL MODELS SUGGESTING NEW LINKS BETWEEN IMMUNOSUPPRESSION AND LYMPHOMA DEVELOPMENT.
P. Ebbesen, Aarhus, Denmark

3:20  24  THE IMPACT OF MOLECULAR BIOLOGY ON THE DIAGNOSIS, PREDICTION OF PROGNOSIS, AND CLINICAL MANAGEMENT OF THE LYMPHOMA PATIENT.
C.L. Willman, ALBUQUERQUE, MEXICO

3:40  25  PHENOTYPIC AND FUNCTIONAL MARKERS RELEVANT TO THE DIAGNOSIS AND PROGNOSIS OF NON HODGKIN'S LYMPHOMAS.
D. Delia, Milan, Italy

4:00  26  HIGH FREQUENCY OF EPSTEIN-BARR VIRUS GENOME IN LYMPH NODES INVOLVED BY HODGKIN'S DISEASE IN HIV+ PATIENTS.
S. Uccini, ET AL, ROME, ITALY

4:15  27  EXPRESSION OF THE BCL-2 ONCOGENE PRODUCT IN FOLLICULAR LYMPHOMA.
D.Y. Mason, ET Al, OXFORD, UNITED KINGDOM
THURSDAY, JUNE 7, 1990
3:00 - 5:30 P.M. (CONTINUED)

4:30  28  DIRECT SEQUENCE ANALYSIS OF 14q+ AND 18q- CHROMOSOME JUNCTIONS AT THE MBR AND MCR REVEALING CLUSTERING WITHIN THE MBR IN FOLLICULAR LYMPHOMA.
   F.E. Cotter, et al, London, United Kingdom

4:45  29  HETEROGENEITY OF AGGRESSIVE LYMPHOMAS BY PLOIDY AND PROLIFERATIVE ACTIVITY. MORPHOLOGIC AND PROGNOSTIC IMPLICATIONS.
   P. Felman, et al, Lyon, France

5:00  30  α, β AND γ,δ T-CELL RECEPTORS IN PERIPHERAL T-CELL LYMPHOMA.
   Ph. Gaulard, et al, Creteil, France

5:15  31  KI67 AND 4F2 ANTIGEN EXPRESSION AS WELL AS DNA SYNTHESIS PREDICT SURVIVAL AT RELAPSE/TUMOUR PROGRESSION IN LOW-GRADE B-CELL LYMPHOMA.
   H. Holte, et al, Oslo, Norway

Session 5 - LYMPHOMA IN CHILDHOOD (Room C)
Chairpersons: S.B. Murphy and G. Schellong

3:00 - 5:35 P.M.

3:00 P.M.  32  HODGKIN'S DISEASE IN CHILDREN: TREATMENT REDUCTION BY ELIMINATION OF PROCARBAZINE FROM OPPA/COPP CHEMOTHERAPY. RESULTS OF THE GERMAN COOPERATIVE STUDY DAL-HD-85.
   G. Schellong, et al, Münster, West-Germany

3:15  33  HIGH-DOSE COMBINATION CHEMOTHERAPY FOR CHILDHOOD HODGKIN'S DISEASE: THE FRENCH PEDIATRIC ONCOLOGY SOCIETY EXPERIENCE.
   O. Oberlin, et al, Villejuif, France

3:30  34  MALIGNANT HISTIOCYTOSIS AND LARGE CELL ANAPLASTIC (KI-1) LYMPHOMA IN CHILDREN AND ADOLESCENTS - PRELIMINARY EXPERIENCES OF THE BFM STUDY GROUP.
   P. Bugsky, et al, Hannover, West-Germany

3:45  35  ANAPLASTIC LARGE-CELL LYMPHOMA (KI-1+/CD30+) IN CHILDHOOD.
   V. Vecchi, et al, Bologna, Italy

4:00  36  PROLONGED DISEASE FREE SURVIVAL IN PEDIATRIC NON-HODGKIN'S LYMPHOMA USING IFOSFAMIDE CONTAINING COMBINATION CHEMOTHERAPY.
   N. Gad-El-Mawla, et al, Cairo, Egypt
THURSDAY, JUNE 7, 1990
3:00 - 5:35 P.M. (CONTINUED)

4:15  37  IFOSFAMIDE IN THE TREATMENT OF HIGH-GRADE, RECURRENT B CELL LYMPHOMAS: EXPERIENCE OF THE PEDIATRIC BRANCH, NATIONAL CANCER INSTITUTE.
I.T. MAGRATH, ET AL, BETHESDA, USA

4:30  38  BFM THERAPY STRATEGY AND RESULTS IN ADVANCED CHILDHOOD B-CELL NEOPLASIAS (STAGE-IV, B-NHL, B-ALL).
A. REITER, ET AL, HANNOVER, WEST-GERMANY

4:45  39  HIGH SURVIVAL RATE OF B-CELL NON HODGKIN'S LYMPHOMAS WITH CNS INVOLVEMENT AND B-ALL.
C. PATTE, ET AL, VILLEJUIF, FRANCE

5:00  40  RESULTS OF TREATMENT FOR ADVANCED STAGE DIFFUSE SMALL-NON-CLEAVED CELL NON-HODGKINS LYMPHOMAS AND B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: THE PEDIATRIC ONCOLOGY GROUP EXPERIENCE, 1986-89.
S.B. MURPHY, CHICAGO, USA

5:15

FRIDAY, JUNE 8, 1990
8:00 - 9:00 A.M.

POSTER SESSION III (VILLA CIANI)
STUDIES IN NHL

SESSION 6 - BIOLOGY OF LYMPHOMAS II (ROOM A)
CHAIRMEN: M. PFREUNDSCHUH AND R. ZITTOU

9:00 - 11:50 A.M.

9:00 A.M.  41  EPIDEMIOLOGICAL, PATHOLOGICAL, SEROLOGICAL AND CLINICAL STUDIES OF MALIGNANT LYMPHOMAS IN CHINA.
Y. SUN, BEIJING, CHINA

9:15  42  T-CELL LYMPHOMA IN JAPAN.
M. SHIMOYAMA, TOKYO, JAPAN

9:35  43  NEW INSIGHTS IN THE BIOLOGY OF LYMPHOMAS.
L.M. NADLER, BOSTON, USA
Friday, June 8, 1990
9:00 - 11:50 A.M. (continued)

10:00  44  The significance of B-clonal excess in peripheral blood in patients with non-Hodgkin's lymphoma in clinical complete remission.
        A. Johnson, et al, Lund, Sweden

10:15  

10:30  45  Idiotype expression, sharing and remodeling in follicular lymphoma.
        R. Levy, Stanford, USA

10:50  46  Analysis of T(14;18) chromosomal breakpoints by polymerase chain reaction and direct DNA sequencing in B-cell lymphoma.
        M. Kneba, et al, Göttingen, West-Germany

1:05  47  Expression of growth-related genes and drug-resistance genes in HTLV-1-positive and HTLV-1-negative post-thymic T cell malignancies.
        I.J. Su, Taipei, Taiwan

        J. Armitage, et al, Omaha, USA

11:35  49  Clinical relevance of myelomonocytic antigen CD13 (aminopeptidase N) expression in B-cell chronic lymphocytic leukemia.
        A. Pinto, et al, Aviano, Italy

12:00 Noon  
Lunch (Room B)

1:00-1:45 P.M.  50  Key note lecture (Room A)
        The role of growth factors in haemopoiesis: biological and clinical implications.
        T.M. Dexter, Manchester, United Kingdom

Session 7 - General Session on NHL (Room A)
Chairman: J.E. Ullmann

1:50 - 2:50 P.M.

1:50  51  Management of follicular lymphoma.
        T.A. Lister, London, United Kingdom

2:20  52  The present status of therapy for patients with aggressive non Hodgkin's lymphoma.
        J.O. Armitage, Omaha, USA
**Session 8 - Proffered Papers on NHL (Room A)**
Chairpersons: S. Horning and R. Somers

2:55 P.M. 53
MORPHOLOGIC PROGNOSTIC FACTORS IN FOLLICULAR LYMPHOMAS. A RETROSPECTIVE STUDY OF 127 PATIENTS.
B. COIFFIER, ET AL, PIERRE BENITE, FRANCE

3:10 54
STAGE I-II LOW-GRADE LYMPHOMAS: A PROSPECTIVE TRIAL OF COMBINATION CHEMOTHERAPY AND RADIOTHERAPY.
P. McLAUGHLIN, ET AL, HOUSTON, USA

3:25 55
INTERFERON-α₂b AS INITIAL THERAPY IN COMBINATION WITH CHLORAMBUICIL AND AS MAINTENANCE THERAPY IN FOLLICULAR LYMPHOMA.
C. PRICE, LONDON, UNITED KINGDOM

3:40
REPORT ABOUT WORKSHOP ON PROGNOSTIC FACTORS IN AGGRESSIVE NHL.
G.P. CANELLOS, BOSTON, USA

4:00 56
SUPERIORITY OF SECOND VERSUS FIRST GENERATION CHEMOTHERAPY IN A RANDOMIZED TRIAL FOR STAGE III-IV AGGRESSIVE NON HODGKIN LYMPHOMA: THE 1980-1985 EORTC TRIAL.
P. CARDE, ET AL, VILLEJUIF, FRANCE

4:15 57
PROSPECTIVE MULTICENTER TRIAL FOR THE RESPONSE-ADAPTED TREATMENT OF HIGH-GRADE MALIGNANT NON-HODGKIN LYMPHOMAS: UPDATED RESULTS OF THE COP-BLAM/IMVP-16 PROTOCOL WITH RANDOMIZED ADJUVANT RADIOTHERAPY.
M. ENGELHARD, ET AL, ESSEN, WEST-GERMANY

4:30 58
TREATMENT OF INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMAS WITH THIRD GENERATION CHEMOTHERAPY REGIMENS: ANALYSIS OF SOUTHWEST ONCOLOGY GROUP, PHASE II STUDIES.
R.I. FISHER, ET AL, MAYWOOD, USA

4:45 59
CHEMOTHERAPY FOR ELDERLY PATIENTS WITH ADVANCED STAGE LARGE CELL LYMPHOMA - A LITTLE GOES A LONG WAY.
S. O'REILLY, ET AL, VANCOUVER

5:00 60
NON HODGKIN'S LYMPHOMAS ASSOCIATED WITH HUMAN IMMUNODEFICIENCY VIRUS: TREATMENT BY LNH 84 REGIMEN.
C. GISSELBRECHT, ET AL, PARIS, FRANCE

5:15 61
TREATMENT OF RELAPSES IN THE SFOP LMB 0384 PROTOCOL. ROLE OF BONE MARROW TRANSPLANTATION AS SALVAGE THERAPY.
T. PHILIP, ET AL, LYON, FRANCE
5:30  62  AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR ADULT
LYMPHOBLASTIC LYMPHOMA IN FIRST COMPLETE REMISSION. A PILOT
STUDY OF THE NON-HODGKIN’S LYMPHOMA CO-OPERATIVE STUDY
GROUP.
G. Santini, et al, Genua, Italy

5:45  63  AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR INCURABLE
ADVANCED STAGE B CELL NON-HODGKIN’S LYMPHOMA IN FIRST
REMISSION.
A. Freedman, et al, Boston, USA

SESSION 9 - WORKSHOP ON GROWTH FACTORS (ROOM B1)
CHAIRMAN: D. Crowther

3:00 P.M.  64  REGULATION OF NORMAL AND MALIGNANT LYMPHOCYTE
DIFFERENTIATION AND FUNCTION BY TRANSFORMING GROWTH
FACTOR-β.
M.B. Sporn, Bethesda, USA

3:30  65  THE BIOLOGY OF INTERLEUKIN 6: THE ROLE IN PLASMA CELL
DISEASES.
B.G.M. Durie, London, United Kingdom

4:00  66  HAEMOPOIETIC GROWTH FACTORS: CLINICAL ROLE.
D. Crowther, Manchester, United Kingdom

4:30  67  ROLE OF GM-CSF IN TREATMENT OF MALIGNANT LYMPHOMAS.
D. Hovgaard, et al, Copenhagen, Denmark

4:45  68  RECOMBINANT HUMAN GM-CSF AND MITOXANTRONE/HIGH-DOSE ARA-C
IN THE TREATMENT OF REFRACTORY NON-HODGKIN-LYMPHOMA.
A.D. Ho, et al, Heidelberg, West-Germany

5:00  69  A PROSPECTIVE RANDOMIZED TRIAL COMPARING RECOMBINANT
GRANULOCYTE COLONY STIMULATING FACTOR VS PLACEBO FOR
NEUTROPENIA INDUCED BY CHEMOTHERAPY IN PATIENTS WITH
NON-HODGKIN LYMPHOMA.
M. Ogawa, et al, Tokyo, Japan
ASSOCIATION OF LYMPHOCYTE HOMING RECEPTOR EXPRESSION AND STAINING INTENSITY WITH S-PHASE FRACTION, STAGE, AND PROGNOSIS IN NON-HODGKIN'S LYMPHOMA.
H. Joensuu, et al., Turku, Finland

SECONDARY B-CELL LYMPHOMAS DEVELOPING IN TWO PATIENTS WITH ADULT T-CELL LEUKEMIA.
K. Tobinai, et al., Tokyo, Japan

LARGE CELL ANAPLASTIC Ki-1 POSITIVE LYMPHOMA. A STUDY OF 5 CASES.
C.C. De Bruyn, et al., Natal, South Africa

MEDIASTINAL LARGE CELL LYMPHOMAS. A HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY.
M.F. D'Agay, et al., Paris, France

PRIMARY GASTRIC NON-HODGKIN LYMPHOMAS. DOES THE CONCEPT OF "MUCOSA-ASSOCIATED LYMPHOMA" HAVE ANY CLINICAL RELEVANCE?
A. Johnsson, et al., Lund, Sweden

PRIMARY GASTRIC LYMPHOMA: CLINICAL AND PROGNOSTIC FEATURES OF 145 CASES.
S.B. Cooliatti, et al., Kiel, West-Germany

THE PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL PATTERN IN PRIMARY GASTRIC LYMPHOMA: AN ANALYSIS OF 80 PATIENTS.
K.A. MacLennan, et al., London, United Kingdom

MALIGNANT LYMPHOMA OF GASTROINTESTINAL TRACT: ANALYSIS OF CLINICOPATHOLOGICAL FEATURES AND TREATMENT RESULTS.
M. Ben-Shahar, et al., Jerusalem, Israel

NON-HODGKIN LYMPHOMA OF WALDEYER'S RING LYMPHOID TISSUE: PRESENTATION AND PROGNOSIS.
J. Raemaekers, et al., Nijmegen, The Netherlands

PRIMARY CEREBRAL MALIGNANT NON-HODGKIN'S LYMPHOMAS. HISTOLOGICAL AND IMMUNOMORPHOLOGICAL FINDINGS ON STEREOTACTIC BRAIN BIOPSIES.
K. Schuchheimann, et al., Freiburg, West-Germany

CHROMOSOMAL ABNORMALITIES IN UNTREATED PATIENTS WITH NON-HODGKIN'S LYMPHOMA HAVE AN INDEPENDENT PROGNOSTIC VALUE FOR TREATMENT OUTCOME.
H.C. Schouten, et al., Maastricht, The Netherlands
LONGTERM FOLLOW UP OF 1520 NHL PATIENTS CLASSIFIED ACCORDING TO THE KIEL CLASSIFICATION – EXPERIENCES OF A SINGLE INSTITUTION.
R. HEINZ, VIENNA, AUSTRIA

SESSION 11 - FUTURE PROSPECTS (Room A)
CHAIRMEN: F. CAVALLI AND J.E. ULMANN

TREATMENT OF AGGRESSIVE LYMPHOMAS IN PATIENTS OLDER THAN 69 YEARS. FIRST INTERIM REPORT OF A RANDOMIZED STUDY FROM THE G.E.L.A.
B. COIFFIER, ET AL, PIERRE BENITE, FRANCE

SUMMARY OF WORKSHOP ON NEW DIAGNOSTIC TOOLS.
C.M. BERARD, MEMPHIS, USA

ABLATIVE THERAPY WITH AUTOLOGOUS BONE MARROW TRANSPLANTATION AS CONSOLIDATION THERAPY FOR FOLLICULAR LYMPHOMA.
A.Z.S. ROHATINER, LONDON, UNITED KINGDOM

THERAPY WITH IMMUNOTOXINS.
L.M. NADLER, BOSTON, USA

RADIO-IMMUNOTHERAPY OF NON-HODGKIN'S LYMPHOMA WITH SINGLE HIGH DOSE I-131 RADIOLABELED ANTIBODIES.
J.F. EARY, SEATTLE, USA

AUTOLOGOUS LYMPHOCYTES AS VECTORS TO TARGET THERAPEUTIC RADIATION IN PATIENTS WITH DIFFUSE LYMPHOMA LYMPHOCYTIC.
R.A. COWAN, ET AL, MANCHESTER, UNITED KINGDOM

SUMMARY OF THE CONFERENCE
J.E. ULMANN, CHICAGO, USA